Sponsor Directory

AstraZeneca clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 3:43 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1904

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Healthy Young Adults, Influenza Vaccines, Influenza Vaccine Response
Interventions: FluMist, inactivated influenza vaccine, bronchoscopy; Biological · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 40 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Head and Neck Cancer
Interventions: Oral Decitabine, Durvalumab, 5' Azacitidine, Tremelimumab; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Participants
Interventions: AZD2389, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Glendale, California

Conditions: Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
Interventions: Cotadutide, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 29
States / cities: Tucson, Arizona • Canoga Park, California • Gilroy, California + 23 more

Conditions: Sarcoma, Sarcoma Metastatic
Interventions: Olaparib, Trabectedin; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 16 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Mitiperstat (AZD4831), Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 19
States / cities: Newport Beach, California • Clearwater, Florida • DeLand, Florida + 16 more

Conditions: Advanced Solid Tumours
Interventions: Ceralasertib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 12
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 9 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Treatment A (BGF MDI HFO with oral activated charcoal), Treatment B (BGF MDI HFA with oral activated charcoal); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Interventions: BGF MDI HFO 320/14.4/9.6μg, BGF MDI HFA 320/14.4/9.6 μg, Placebo MDI HFA; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 19
States / cities: Sheffield, Alabama • Clearwater, Florida • Gainesville, Florida + 16 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: BGF, MITT; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 22,369 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Heart Failure With Preserved Ejection Fraction
Interventions: AZD4831, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 711 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 21
States / cities: Alexander City, Alabama • Little Rock, Arkansas • Sacramento, California + 18 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Treatment A: BGF MDI HFO, Treatment B: BGF MDI HFA; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Glendale, California

About this AstraZeneca sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where AstraZeneca is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within AstraZeneca trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

AstraZeneca clinical trials

Filter and sort this sponsor

Live official records

Characterizing the Human Airway Immune Response to FluMist Vaccination

Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients

A Single and Multiple Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2389 in Healthy Participants

A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma

An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.

A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant

A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD

A Comparative Effectiveness Study of Mortality Outcomes and Related Cardiopulmonary Events Among a Cohort of Chronic Obstructive Pulmonary Disease (COPD) Patients Who Initiate Breztri and Multiple Inhaler Triple Therapy (MITT) in the United States (US)

Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%

A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant

About this AstraZeneca sponsor directory page